Hormone replacement therapy, inflammation, and hemostasis in elderly women - PubMed (original) (raw)
Multicenter Study
Hormone replacement therapy, inflammation, and hemostasis in elderly women
M Cushman et al. Arterioscler Thromb Vasc Biol. 1999 Apr.
Abstract
Lipid-lowering by postmenopausal hormone therapy (HRT) explains only partly the assumed coronary risk reduction associated with therapy. To explore other possible mechanisms, we studied associations of HRT use with inflammation and hemostasis risk markers in women >/=65 years of age. Subjects were selected from 3393 participants in the fourth year examination of the Cardiovascular Health Study, an observational study of vascular disease risk factors. After excluding women with vascular disease, we compared levels of inflammation and hemostasis variables in the 230 women using unopposed estrogen and 60 using estrogen/progestin, with those of 196 nonusers selected as controls. Compared with nonusers, unopposed estrogen use was associated with 59% higher mean C-reactive protein (P<0.001), but with modestly lower levels of other inflammation indicators, fibrinogen, and alpha-1 acid glycoprotein (P<0.001). Factor VIIc was 16% higher among estrogen users (P<0.001), but this was not associated with higher thrombin production (prothrombin fragment 1-2), or increased fibrin breakdown (D-dimer). Concentration of plasminogen activator inhibitor-1 was 50% lower in both using groups (P<0.001) compared with nonusers, and this was associated with higher plasmin-antiplasmin complex: 8% higher in estrogen and 18% higher in estrogen/progestin users (P<0. 05). Relationships between the markers and hormone use were less pronounced in estrogen/progestin users, with no association for C-reactive protein except in women in upper 2 tertiles of body mass index (P for interaction, 0.02). The direction and strength of the associations of HRT use with inflammation markers differed depending on the protein, so it is not clear whether HRT confers coronary risk reduction through an inflammation-sensitive mechanism. Associations with hemostasis markers indicated no association with evidence of procoagulation and a possible association with increased fibrinolytic activity.
Similar articles
- Relationship of physical fitness, hormone replacement therapy, and hemostatic risk factors in postmenopausal women.
Szymanski LM, Kessler CM, Fernhall B. Szymanski LM, et al. J Appl Physiol (1985). 2005 Apr;98(4):1341-8. doi: 10.1152/japplphysiol.00622.2004. Epub 2004 Dec 10. J Appl Physiol (1985). 2005. PMID: 15591298 Clinical Trial. - Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study.
Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE, Hendrix SL, LaCroix AZ, Ridker PM. Langer RD, et al. Thromb Haemost. 2005 Jun;93(6):1108-16. doi: 10.1160/TH04-09-0608. Thromb Haemost. 2005. PMID: 15968396 - Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
Ross RK, Paganini-Hill A, Wan PC, Pike MC. Ross RK, et al. J Natl Cancer Inst. 2000 Feb 16;92(4):328-32. doi: 10.1093/jnci/92.4.328. J Natl Cancer Inst. 2000. PMID: 10675382 - Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women.
Koh KK. Koh KK. Int J Hematol. 2002 Aug;76 Suppl 2:44-6. doi: 10.1007/BF03165085. Int J Hematol. 2002. PMID: 12430899 Review. - Comparative cardiovascular effects of different progestins in menopause.
Rosano GM, Fini M. Rosano GM, et al. Int J Fertil Womens Med. 2001 Sep-Oct;46(5):248-56. Int J Fertil Womens Med. 2001. PMID: 11720197 Review.
Cited by
- The influence of inflammation on cardiovascular disease in women.
Kottilil S, Mathur P. Kottilil S, et al. Front Glob Womens Health. 2022 Oct 11;3:979708. doi: 10.3389/fgwh.2022.979708. eCollection 2022. Front Glob Womens Health. 2022. PMID: 36304737 Free PMC article. Review. - The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis.
Schutte MH, Kleemann R, Nota NM, Wiepjes CM, Snabel JM, T'Sjoen G, Thijs A, den Heijer M. Schutte MH, et al. PLoS One. 2022 Mar 15;17(3):e0261312. doi: 10.1371/journal.pone.0261312. eCollection 2022. PLoS One. 2022. PMID: 35290388 Free PMC article. - 100 YEARS OF VITAMIN D: Combined hormonal contraceptives and vitamin D metabolism in adolescent girls.
Öberg J, Jorde R, Figenschau Y, Thorsby PM, Dahl SR, Winther A, Grimnes G. Öberg J, et al. Endocr Connect. 2022 Mar 31;11(3):e210395. doi: 10.1530/EC-21-0395. Endocr Connect. 2022. PMID: 35213326 Free PMC article. - Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative.
Cushman M, Larson JC, Rosendaal FR, Heckbert SR, Curb JD, Phillips LS, Baird AE, Eaton CB, Stafford RS. Cushman M, et al. Res Pract Thromb Haemost. 2018 Apr 17;2(2):310-319. doi: 10.1002/rth2.12100. eCollection 2018 Apr. Res Pract Thromb Haemost. 2018. PMID: 30046733 Free PMC article. - Soluble Inflammatory Markers and Risk of Incident Fractures in Older Adults: The Cardiovascular Health Study.
Stojanović D, Bůžková P, Mukamal KJ, Heckbert SR, Psaty BM, Fink HA, Cauley JA, Wallace E, Curtis LH, Hirsch C, Budoff M, Li D, Young R, Jalal D, Delaney JA. Stojanović D, et al. J Bone Miner Res. 2018 Feb;33(2):221-228. doi: 10.1002/jbmr.3301. Epub 2017 Nov 6. J Bone Miner Res. 2018. PMID: 28976598 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials